Evidence map›Paper›PMID 39143250›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2024

Standardized template for clinical reporting of PSMA PET/CT scans.

Shadi A Esfahani, Michael J Morris, Oliver Sartor, Mark Frydenberg, Stefano Fanti, Jeremie Calais, Neha Vapiwala

Abstract read
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Shadi A EsfahaniDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. Esfahani.Shadi@mgh.harvard.edu.
Michael J MorrisGenitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Oliver SartorDepartment of Medical Oncology, Mayo Clinic, Minnesota, USA.
Mark FrydenbergDepartment of Surgery, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Australia.
Stefano FantiIRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Jeremie CalaisAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, University of California, Los Angeles, CA, USA.
Neha VapiwalaDepartment of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USA.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
Molecular Imaging of Fibrosis for Improved Treatment Planning of Pancreatic Ductal AdenocarcinomaK08CA259626 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Shadi Abdar Esfahani · 2022 to 2026
$1.3M
NCI NIH HHS K08 CA259626NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

purposeAccurate diagnosis and staging of prostate cancer are crucial to improving patient care. Prostate-specific membrane antigen (PSMA)-targeted positron emission tomography with computed tomography (PET/CT) imaging has demonstrated superiority for initial staging and restaging in patients with prostate cancer. Referring physicians and PET/CT readers must agree on a consistent communication method and application of information derived from this imaging modality. While several guidelines have been published, a single PSMA PET/CT reporting template has yet to be widely adopted. Based on the consensus from community and academic physicians, we developed a standardized PSMA PET/CT reporting template for radiologists and nuclear medicine physicians to report and relay key imaging findings to referring physicians. The aim was to improve the quality, clarity, and utility of imaging results reporting to facilitate patient management decisions.

methodsBased on community and expert consensus, we developed a standardized PSMA PET/CT reporting template to deliver key imaging findings to referring clinicians.

resultsCore category components proposed include a summary of any prior treatment history; presence, location, and degree of PSMA radiopharmaceutical uptake in primary and/or metastatic tumor(s), lesions with no uptake, and incidentally found lesions with positive uptake on PET/CT.

conclusionsThis article provides recommendations on best practices for standardized reporting of PSMA PET/CT imaging. The generated reporting template is a proposed supplement designed to educate and improve data communication between imaging experts and referring physicians.

Indexed as

Antigens, SurfaceGlutamate Carboxypeptidase IIPositron Emission Tomography Computed TomographyProstatic NeoplasmsHumansMaleReference StandardsAntigens, SurfaceFOLH1 protein, humanGlutamate Carboxypeptidase IIGuidelinePET/CTProstate cancerPSMAReport

Identifiers

PMID39143250
PMCPMC11599343

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.